Relay Therapeutics develops small molecule drugs for patients with cancer and genetic disease. RLAY reports earnings on Wed, Nov 4, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in RLAY, 0% of them bullish and 100% bearish. In the past 30 days there were 5 dark pool prints.
Prices, price targets and earnings estimates for RLAY are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RLAY is in one of them and how their past RLAY trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Relay Therapeutics
Relay Therapeutics is a biotechnology company based in Cambridge, Massachusetts, that develops small molecule drugs for patients with cancer and genetic disease. Its work centers on its Dynamo platform, which uses computational and experimental methods to study how proteins move and to design drugs for protein targets that conventional approaches have struggled to address. Its lead candidate, zovegalisib, is in clinical trials for breast cancer and for vascular anomalies. The company is still testing its therapies, so it does not yet sell medicines to patients.
